Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

Inclusion Criteria Patient must have the following: * AIDS as defined by CDC criteria. * Retinitis as diagnosed by the study ophthalmologist. * Performance status 0, 1, or 2. * Ability to give informed consent and suitability of intravenous access for scheduled blood tests. * Patient may have Kaposi's sarcoma or basal skin cancer. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Active acute infection requiring treatment. * Corneal, lens, or vitreal opacification which precludes examination of the fundi, or evidence of retinopathy. * Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer. Patients with the following are excluded: * Active acute infection requiring treatment. * Corneal, lens, or vitreal opacification which precludes examination of the fundi, or evidence of retinopathy. * Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer. Prior Medication: Excluded: * Granulocyte macrophage colony-stimulating factor (GM-CSF). * Colony stimulating factor. * Interleukin 3. * Excluded within 7 days of study entry: * Zidovudine (AZT). * Trimethoprim / sulfamethoxazole (TMP / SMX). * Pyrimethamine. * Excluded within 30 days of study entry: * Biologic response modifiers. * Cytotoxic agents. * Investigational agents. Prior Treatment: Excluded: * Radiation therapy. Required within 1 week of study entry: * One or more doses of ganciclovir.